Applied Nutrition PLC (GB:APN)
LSE:APN
Top Page
Applied Nutrition PLC
(LSE:APN)
Select Model
Select Model
Rating:70Outperform
Price Target:
226.00 p
▼(-2.38% Downside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by very strong financial performance (rapid revenue/earnings growth, low leverage, and strong free cash flow), partially offset by weak technicals (price below key moving averages and negative MACD). Valuation is supportive with a moderate P/E, but no dividend yield data is available.
Positive Factors
Revenue Growth
Sustained top-line expansion from £35m to £107.1m over four years indicates durable market demand and successful scaling. That multi-year growth supports operating leverage, wider distribution and category presence, improving long-term revenue predictability and competitive position.
Negative Factors
Margin Softening
A modest decline in margins signals emerging cost pressures or margin dilution as scale increases. If sustained, it could erode return on invested capital and require either pricing power or tighter cost control to preserve long-term profitability and cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line expansion from £35m to £107.1m over four years indicates durable market demand and successful scaling. That multi-year growth supports operating leverage, wider distribution and category presence, improving long-term revenue predictability and competitive position.
Read all positive factors
Applied Nutrition PLC (APN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£542.50M
Dividend YieldN/A
Average Volume (3M)256.26K
Price to Earnings (P/E)9.5
Beta (1Y)0.72
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees270
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)N/A
Shares Outstanding250,000,000
10 Day Avg. Volume266,481
30 Day Avg. Volume256,256
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)6.03
Price to Sales (P/S)3.06
P/FCF Ratio21.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£301.67Price Target Upside30.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Applied Nutrition PLC Business Overview & Revenue Model
Company Description
Applied Nutrition Plc engages in the manufacture, wholesale, and retail of sports nutritional products in the United Kingdom and internationally. It offers whey protein, whey protein isolate, casein protein powder, clear protein, vegan protein, pr...
How the Company Makes Money
null...
Applied Nutrition PLC Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 134.00M | 107.10M | 86.15M | 60.78M | 35.03M |
| Gross Profit | 60.40M | 48.20M | 40.38M | 26.51M | 13.61M |
| EBITDA | 38.90M | 29.70M | 25.38M | 18.61M | 10.42M |
| Net Income | 27.60M | 21.10M | 18.65M | 13.82M | 8.21M |
Balance Sheet | |||||
| Total Assets | 98.90M | 75.00M | 59.65M | 40.62M | 22.11M |
| Cash, Cash Equivalents and Short-Term Investments | 26.40M | 18.50M | 18.72M | 12.73M | 5.40M |
| Total Debt | 3.10M | 3.00M | 1.80M | 2.06M | 1.13M |
| Total Liabilities | 29.30M | 20.70M | 11.63M | 11.87M | 7.24M |
| Stockholders Equity | 69.60M | 54.30M | 48.02M | 28.75M | 14.87M |
Cash Flow | |||||
| Free Cash Flow | 16.30M | 15.20M | 6.28M | 7.62M | 6.20M |
| Operating Cash Flow | 17.20M | 16.20M | 7.32M | 8.59M | 6.49M |
| Investing Cash Flow | -900.00K | -1.00M | -407.00K | -989.00K | -267.00K |
| Financing Cash Flow | -800.00K | -15.10M | -339.00K | -217.00K | -8.98M |
Applied Nutrition PLC Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £2.81B | 8.36 | 14.71% | 2.06% | 6.96% | 28.47% | |
76 Outperform | £1.61B | 8.95 | 10.71% | 1.62% | 0.50% | 20.52% | |
70 Outperform | £1.94B | 17.26 | 12.20% | 0.79% | 7.74% | 30.09% | |
70 Outperform | £542.50M | 9.46 | 44.55% | ― | ― | ― | |
69 Neutral | £13.30B | 15.47 | 9.22% | 2.98% | -3.06% | -26.93% | |
65 Neutral | £1.56B | 8.87 | 2.17% | 5.27% | 26.84% | -81.73% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
GB:APN
Applied Nutrition PLC
217.00
105.00
93.75%
GB:ABF
Associated British Foods
1,890.50
66.10
3.62%
GB:CWK
Cranswick
5,250.00
716.13
15.80%
GB:PFD
Premier Foods
186.60
10.11
5.73%
GB:TATE
Tate & Lyle
352.20
-109.32
-23.69%
GB:GNC
Greencore
244.00
75.00
44.38%
Applied Nutrition PLC Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Applied Nutrition posts 57% revenue surge and boosts capacity in strong first half
Positive
Mar 23, 2026
Applied Nutrition reported a strong first half to 31 January 2026, with revenue jumping 57% year-on-year to £74.5m, adjusted EBITDA up 56% to £21.5m and profit before tax up 54% to £20.9m, all ahead of management expectations. The g...
Business Operations and StrategyFinancial Disclosures
Applied Nutrition lifts full-year revenue outlook after 57% H1 sales surge
Positive
Feb 17, 2026
Applied Nutrition reported a strong first half to its 2026 financial year, with revenue rising 57% to £74.5 million versus the prior period and EBITDA exceeding management expectations. The performance was driven by successful channel diversi...
Business Operations and Strategy
Applied Nutrition Strengthens City Support With Appointment of Joint Broker
Positive
Jan 12, 2026
Applied Nutrition plc has appointed Panmure Liberum Limited as a joint corporate broker, working alongside existing brokers Deutsche Numis and Goodbody, in a move that enhances its capital markets advisory and brokerage support. The expanded broke...
Business Operations and StrategyStock BuybackShareholder Meetings
Applied Nutrition Wins Strong Shareholder Backing for All AGM Resolutions
Positive
Jan 8, 2026
Applied Nutrition plc confirmed that all 18 resolutions at its 8 January 2026 Annual General Meeting were approved by shareholders via poll, including the receipt of the 2025 annual report, approval of the directors’ remuneration report and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.